Label: HYDROXYZINE HYDROCHLORIDE - hydroxyzine hydrochloride tablet, film coated 

  • Label RSS
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated 02/12

If you are a consumer or patient please visit this version.

  • DESCRIPTION

    HydrOXYzine hydrochloride has the chemical name of 2-[2-[4-(p-Chloro-α-phenylbenzyl)-1-piperazinyl]ethoxy] ethanol dihydrochloride.

    177e24c2-figure-01

    C21H27ClN202•2HCI                                                                                   M.W. 447.83

    HydrOXYzine hydrochloride occurs as a white, odorless powder which is very soluble in water.

    Each tablet for oral administration contains 10 mg, 25 mg or 50 mg hydrOXYzine HCl. Inactive ingredients include anhydrous lactose, carnauba wax, colloidal silicon dioxide,

    crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, sodium starch glycolate, titanium dioxide, and triacetin.

    Close
  • CLINICAL PHARMACOLOGY

    HydrOXYzine hydrochloride is unrelated chemically to the phenothiazines, reserpine, meprobamate or the benzodiazepines. HydrOXYzine is not a cortical depressant, but its action may be due to a suppression of activity in certain key regions of the subcortical area of the central nervous system.

    Primary skeletal muscle relaxation has been demonstrated experimentally. Bronchodilator activity, and antihistaminic and analgesic effects have been demonstrated experimentally and confirmed clinically. An antiemetic effect, both by the apomorphine test and the veriloid test, has been demonstrated.

    Pharmacological and clinical studies indicate that hydrOXYzine in therapeutic dosage does not increase gastric secretion or acidity and in most cases has mild antisecretory

    activity.

    HydrOXYzine is rapidly absorbed from the gastrointestinal tract and HydrOXYzine’s clinical effects are usually noted within 15 to 30 minutes after oral administration.

    Close
  • INDICATIONS AND USAGE

    For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested.

    Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histamine-mediated pruritus.

    As a sedative when used as a premedication and following general anesthesia, hydrOXYzine may potentiate meperidine and barbiturates, so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. HydrOXYzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent.

    The effectiveness of hydrOXYzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient.

    Close
  • CONTRAINDICATIONS

    HydrOXYzine, when administered to the pregnant mouse, rat, and rabbit induced fetal abnormalities in the rat and mouse at doses substantially above the human therapeutic range. Clinical data in human beings are inadequate to establish safety in early pregnancy. Until such data are available, hydrOXYzine is contraindicated in early pregnancy.

    HydrOXYzine is contraindicated for patients who have shown a previous hypersensitivity to it.

    Close
  • WARNINGS

    Nursing Mothers: It is not known whether this drug is excreted in human milk. Since many drugs are so excreted, hydrOXYzine should not be given to nursing mothers.

    Close
  • PRECAUTIONS

    THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC

    ANALGESICS AND BARBITURATES. Therefore, when central nervous system depressants are administered concomitantly with hydrOXYzine their dosage should be reduced.

    Since drowsiness may occur with use of this drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery while taking hydrOXYzine. Patients should also be advised against the simultaneous use of other CNS depressant drugs, and cautioned that the effects of alcohol may be increased.

    Geriatric Use: A determination has not been made whether controlled clinical studies of hydrOXYzine included sufficient numbers of subjects aged 65 and over to define a difference in response from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.

    The extent of renal excretion of hydrOXYzine has not been determined. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selections.

    Sedating drugs may cause confusion and over sedation in the elderly; elderly patients generally should be started on low doses of hydrOXYzine and observed closely.

    Close
  • ADVERSE REACTIONS

    Side effects reported with the administration of hydrOXYzine hydrochloride are usually mild and transitory in nature.

    Anticholinergic: Dry mouth.

    Central Nervous System: Drowsiness is usually transitory and may disappear in a few days of continued therapy or upon reduction of dose. Involuntary motor activity including rare instances of tremor and convulsions have been reported, usually with doses considerably higher than those recommended. Clinically significant respiratory depression has not been reported at recommended doses.

    Close
  • OVERDOSAGE

    The most common manifestation of hydrOXYzine overdosage is hypersedation. As in the management of overdosage with any drug, it should be borne in mind that multiple agents may have been taken.

    If vomiting has not occurred spontaneously, it should be induced. Immediate gastric lavage is also recommended. General supportive care, including frequent monitoring of the vital signs and close observation of the patient, is indicated. Hypotension, though unlikely, may be controlled with intravenous fluids and levarterenol or metaraminol. Do not use epinephrine as hydrOXYzine counteracts its pressor action.

    There is no specific antidote. It is doubtful that hemodialysis would be of any value in the treatment of overdosage with hydrOXYzine. However, if other agents such as barbiturates have been ingested concomitantly, hemodialysis may be indicated. There is no practical method to quantitate hydrOXYzine in body fluids or tissue after its ingestion or administration.

    Close
  • DOSAGE AND ADMINISTRATION

    For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested: Adults, 50-100 mg q.i.d.; children under 6 years, 50 mg daily in divided doses; children over 6 years, 50-100 mg daily in divided doses.

    For use in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histamine-mediated pruritus: adults, 25 mg t.i.d. or q.i.d.; children under 6 years, 50 mg daily in divided doses; children over 6 years, 50-100 mg daily in divided doses.

    As a sedative when used as a premedication and following general anesthesia: 50-100 mg for adults and 0.6 mg/kg of body weight in children.

    When treatment is initiated by the intramuscular route of administration, subsequent doses may be administered orally.

    As with all potent medication, the dosage should be adjusted according to the patient's response to therapy.

    Close
  • HOW SUPPLIED

    HydrOXYzine Hydrochloride Tablets, USP are white, round, film coated, biconvex tablets containing 10 mg, 25 mg, or 50 mg of HydrOXYzine Hydrochloride, and supplied as:

    10 mg Tablets: Debossed ‘75’ on one side and ‘A’ on the other

    NDC 67405-575-10                Bottles of 100

    NDC 67405-575-50                Bottles of 500

    NDC 67405-575-96                Bottles of 1000

    25 mg Tablets: Debossed ‘71’ on one side and ‘AN’ on the other

    NDC 67405-671-10                Bottles of 100

    NDC 67405-671-50                Bottles of 500

    NDC 67405-671-96                Bottles of 1000

    50 mg Tablets: Debossed ‘77’ on one side and ‘AN’ on the other

    NDC 67405-577-10                Bottles of 100

    NDC 67405-577-50                Bottles of 500

    NDC 67405-577-96                Bottles of 1000

    STORAGE

    Store at 20°C to 25°C (68°F to 77°F). [See USP Controlled Room Temperature]. Dispense contents with a child-resistant closure (if required) and in a tight container as defined in the USP.

    Close
  • SPL UNCLASSIFIED SECTION

    177e24c2-figure-02Manufactured for:

    HARRIS Pharmaceutical, Inc.

    Fort Myers, FL 33908

    877-RX4-DERM • www.HarrisPharmaceutical.com


    By: Amneal Pharmaceuticals

    Paterson, NJ 07504


    Rev: 11/08

    Close
  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    43063435 Label

    PDRx Label
    Close
  • INGREDIENTS AND APPEARANCE
    HYDROXYZINE HYDROCHLORIDE  
    hydroxyzine tablet, film coated
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:43063-435(NDC:67405-577)
    Route of Administration ORAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    HYDROXYZINE HYDROCHLORIDE (HYDROXYZINE) HYDROXYZINE HYDROCHLORIDE 50 mg
    Inactive Ingredients
    Ingredient Name Strength
    ANHYDROUS LACTOSE  
    CARNAUBA WAX  
    SILICON DIOXIDE  
    CROSPOVIDONE  
    HYPROMELLOSES  
    MAGNESIUM STEARATE  
    CELLULOSE, MICROCRYSTALLINE  
    POLYDEXTROSE  
    POLYETHYLENE GLYCOLS  
    TITANIUM DIOXIDE  
    TRIACETIN  
    SODIUM STARCH GLYCOLATE TYPE A POTATO  
    Product Characteristics
    Color WHITE Score no score
    Shape ROUND Size 7mm
    Flavor Imprint Code AN;77
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:43063-435-12 12 in 1 BOTTLE, PLASTIC
    2 NDC:43063-435-17 17 in 1 BOTTLE, PLASTIC
    3 NDC:43063-435-20 20 in 1 BOTTLE, PLASTIC
    4 NDC:43063-435-25 25 in 1 BOTTLE, PLASTIC
    5 NDC:43063-435-30 30 in 1 BOTTLE, PLASTIC
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    ANDA ANDA040808 06/29/2007
    Labeler - PD-Rx Pharmaceuticals, Inc. (156893695)
    Registrant - PD-Rx Pharmaceuticals, Inc. (156893695)
    Establishment
    Name Address ID/FEI Business Operations
    PD-Rx Pharmaceuticals, Inc. 156893695 repack(43063-435)
    Close